Cagrilintide Dosage Guide
80/100 confidenceComplete guide to Cagrilintide dosing protocols, administration methods, and safety considerations for research purposes.
NOT Medical Advice
The dosage and calculator information provided is for educational and research purposes only. Peptides are not approved by the FDA for human use. Individual responses vary significantly. Always consult with a qualified healthcare professional before making any decisions related to peptide research or use.
Dosage Overview
Dose Range
300 mcg - 600 mcg
Route
subq
Frequency
Weekly
Cycle Length
26-68 weeks
Reconstitution
Vial Size
5 mg
BAC Water
2 ml
Concentration
2,500 mcg/ml
Detailed Dosage Information
Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined.
Administration Method
Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved.
Research Use Only: All dosage ranges and calculations are derived from published research literature and are provided for educational purposes. These are not prescriptions or medical recommendations. Consult a healthcare professional before any use.
Quick Calculator
Concentration: 2,500 mcg/ml
Volume to inject: 0.12 ml
Syringe units (U-100): 12.0 units
Pre-filled with Cagrilintide defaults. Adjust values as needed.
Research Backing
Phase 2/3 RCTs (Lau et al. 2021; Enebo et al.; REDEFINE trials published in NEJM and Lancet) demonstrating 15–20%+ weight loss with acceptable safety.
Side Effects to Monitor
Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially.
Safety Considerations & Risks
Investigational compound - full safety profile being established. Expected to carry similar warnings to approved amylin analog pramlintide.